Shortening Duration of Antiarrhythmic Medication for SVT in Infants
NCT ID: NCT04837261
Last Updated: 2025-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
107 participants
OBSERVATIONAL
2021-04-15
2024-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Management of Supraventricular Tachycardia of Children
NCT03528616
Simulation of Adenosine Push Methods for Treatment of SVT Using Agitated Saline Visualized by Ultrasound
NCT04051541
Use of Antiarrhythmic Drugs in Pediatrics
NCT04863001
Outcome of SVT in Children Admitted to AUCH
NCT07143591
Prospective Evaluation Analysis and Kinetics Registry
NCT05247320
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Propranolol
3 mg/kg/d, divided in four doses when age less than 3 months and in three doses when age more than 3 months
Flecainide
80 mg/m2/d
Amiodarone
Single dose of 10 mg/kg/d 10-14 days, 5 mg/kg/d
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented SVT due to AVRT or AVNRT
Exclusion Criteria
* Ectopic atrial tachycardia
* Atrial flutter
* Atrial fibrillation
* Permanent junctional reciprocating tachycardia
6 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Helsinki University Central Hospital
OTHER
Kuopio University Hospital
OTHER
Oulu University Hospital
OTHER
Turku University Hospital
OTHER_GOV
Tampere University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tuija Poutanen, MD
Role: PRINCIPAL_INVESTIGATOR
Tampere University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Finland Central Hospital
Jyväskylä, Central Finland, Finland
Kajaani Central Hospital
Kajaani, Kainuu, Finland
Hämeenlinna Central Hospital
Hämeenlinna, Kanta-Häme, Finland
Kokkola Central Hopsital
Kokkola, Keski-Pohjanmaa, Finland
Lapland Central Hospital
Rovaniemi, Lapland, Finland
Oulu University Hospital
Oulu, North Ostrobothnia, Finland
Kuopio University Hospital
Kuopio, Northern Savonia, Finland
Lahti Central Hospital
Lahti, Paijat-Hame Region, Finland
Tampere University Hospital
Tampere, Pirkanmaa, Finland
Vaasa Central Hospital
Vaasa, Pohjanmaa, Finland
North Karelia Central Hospital
Joensuu, Pohjois-Karjala, Finland
Kymenlaakso Central Hospital
Kotka, Region of Kymenlaakso, Finland
Sakunta Central Hospital
Pori, Satakunta, Finland
South Karelia Central Hospital
Lappeenranta, South Karelia Region, Finland
Seinäjoki Central Hospital
Seinäjoki, South Ostrobothnia, Finland
Mikkeli Central Hospital
Mikkeli, South Savo, Finland
Turku University Hospital
Turku, Southwest, Finland
Helsinki University Hospital
Helsinki, Uusimaa, Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R20113
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.